CO6331346A2 - Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo - Google Patents

Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo

Info

Publication number
CO6331346A2
CO6331346A2 CO10145550A CO10145550A CO6331346A2 CO 6331346 A2 CO6331346 A2 CO 6331346A2 CO 10145550 A CO10145550 A CO 10145550A CO 10145550 A CO10145550 A CO 10145550A CO 6331346 A2 CO6331346 A2 CO 6331346A2
Authority
CO
Colombia
Prior art keywords
light chain
amino acid
factor
kit
sequences
Prior art date
Application number
CO10145550A
Other languages
English (en)
Inventor
Arthur J Huang
Robert F Kelley
Charles Matthew Winter
Henry B Lowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40999836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6331346(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CO6331346A2 publication Critical patent/CO6331346A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

1.- Un anticuerpo anti-factor D que comprende HVR de cadena ligera de un anticuerpo de referencia, donde dicho anticuerpo anti-factor D comprende además una sustitución en una o más posiciones de dicho anticuerpo, donde dicho anticuerpo de referencia comprende HVR-1 de cadena ligera que contiene ITSTDIDDDMN (identificador de secuencia n.°: 30), cadena ligera HVR-2 que comprende GGNTLRP (identificador de secuencia n.°: 35) y cadena ligera HVR-3 que comprende LQSDSLPYT (identificador de secuencia n.°: 38) donde dicha sustitución es una o más de las siguientes:(a) el aminoácido de la posición 33 de la cadena ligera es L o I,(b) el aminoácido de la posición 34 de la cadena ligera es A o Q,(c) el aminoácido de la posición 52 de la cadena ligera es S o A, (d) el aminoácido de la posición 104 de la cadena ligera es V, (e) el aminoácido de la posición 1 de la cadena pesada es E;(f) el aminoácido de la posición 99 de la cadena pesada es A o Q, (g) el aminoácido de la posición 100 de la cadena pesada es A o Q.
CO10145550A 2008-04-28 2010-11-19 Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo CO6331346A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4843108P 2008-04-28 2008-04-28
US4868908P 2008-04-29 2008-04-29

Publications (1)

Publication Number Publication Date
CO6331346A2 true CO6331346A2 (es) 2011-10-20

Family

ID=40999836

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10145550A CO6331346A2 (es) 2008-04-28 2010-11-19 Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo

Country Status (35)

Country Link
US (7) US8273352B2 (es)
EP (3) EP3002295A1 (es)
JP (2) JP5636359B2 (es)
KR (2) KR101322027B1 (es)
CN (2) CN102066419B (es)
AR (2) AR071510A1 (es)
AU (1) AU2009241348C1 (es)
BR (1) BRPI0907701A2 (es)
CA (2) CA2720853C (es)
CL (2) CL2009001001A1 (es)
CO (1) CO6331346A2 (es)
CR (2) CR20170001A (es)
CY (1) CY1116982T1 (es)
DK (1) DK2283041T3 (es)
EC (1) ECSP10010637A (es)
ES (1) ES2552817T3 (es)
HK (3) HK1147503A1 (es)
HR (1) HRP20151259T1 (es)
HU (1) HUE026349T2 (es)
IL (3) IL208555A (es)
MA (1) MA32300B1 (es)
MX (2) MX2010011342A (es)
MY (1) MY162350A (es)
NZ (3) NZ621103A (es)
PE (2) PE20091783A1 (es)
PH (1) PH12014500519A1 (es)
PL (1) PL2283041T3 (es)
PT (1) PT2283041E (es)
RS (1) RS54405B1 (es)
RU (1) RU2488594C2 (es)
SG (2) SG10201608305SA (es)
SI (1) SI2283041T1 (es)
TW (3) TW201819418A (es)
WO (1) WO2009134711A1 (es)
ZA (1) ZA201301709B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99591C2 (ru) * 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
KR101966712B1 (ko) 2011-03-25 2019-04-09 인텔 코포레이션 분할가능한 엔진에 의해 인스턴스화된 가상 코어를 이용한 코드 블록의 실행을 지원하는 메모리 프래그먼트
WO2013077876A1 (en) * 2011-11-22 2013-05-30 Soft Machines, Inc. A microprocessor accelerated code optimizer
SI2898086T1 (sl) 2012-09-19 2019-03-29 F. Hoffmann-La Roche Ag Načini in sestavki za preprečevanje napačnega vključevanja norlevcina v beljakovine
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2014151043A1 (en) 2013-03-15 2014-09-25 Soft Machines, Inc. A method for emulating a guest centralized flag architecture by using a native distributed flag architecture
CA2914566A1 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
KR20180021234A (ko) * 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
AU2014332021B2 (en) * 2013-10-07 2020-05-07 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
CA2944712A1 (en) * 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA3003647A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
EP3368682B1 (en) 2015-10-30 2019-12-11 H. Hoffnabb-La Roche Ag Methods of measuring factor d activity and potency of factor d inhibitors
JP2018534930A (ja) * 2015-10-30 2018-11-29 ジェネンテック, インコーポレイテッド 抗d因子抗体及びコンジュゲート
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US10421821B2 (en) 2015-10-30 2019-09-24 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
ES2904553T3 (es) * 2015-10-30 2022-04-05 Hoffmann La Roche Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
BR112018010360A2 (pt) * 2015-11-24 2018-12-04 Annexon Inc fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
CN107043422B (zh) * 2016-01-28 2022-01-04 成都康弘生物科技有限公司 抗补体因子D的人源化Fab和人源化抗体及其用途
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3580241A4 (en) 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTIFACTOR D ANTIBODIES AND USES THEREOF
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华(上海)生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
AU2018250695A1 (en) * 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US20200047085A1 (en) * 2018-08-09 2020-02-13 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US5679564A (en) 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO1997038123A1 (en) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
ATE335511T1 (de) 1997-08-26 2006-09-15 Amgen Fremont Inc Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
ES2488819T3 (es) * 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
EP1141285A2 (en) 1998-12-16 2001-10-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP3993746B2 (ja) 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CZ303128B6 (cs) 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 18個のヒト分泌タンパク質
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
ATE435873T1 (de) 2000-03-23 2009-07-15 Genentech Inc Anti-c2/c2a inhibitoren zur komplement aktivierung
DE60136272D1 (de) 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
WO2002030986A2 (en) 2000-10-13 2002-04-18 Biogen, Inc. HUMANIZED ANTI-LT-β-R ANTIBODIES
US20040077575A1 (en) 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
EP1425042B2 (en) 2001-08-17 2016-02-10 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
ES2375490T3 (es) 2004-11-18 2012-03-01 Yale University Métodos y composiciones para diagnosticar degeneración macular relacionada con la edad.
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
CN103920142A (zh) 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
AU2006254979B2 (en) 2005-06-08 2011-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
PL1951279T3 (pl) 2005-10-08 2017-12-29 Apellis Pharmaceuticals, Inc. Kompstatyna i jej analogi w zaburzeniach oczu
UA99591C2 (ru) * 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
EP2158330A2 (en) 2007-05-11 2010-03-03 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CA2721503A1 (en) 2008-04-18 2009-12-03 Massachusetts General Hospital Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
SI2540843T1 (sl) 2008-11-05 2014-10-30 Genentech, Inc. Genetski polimorfizmi in starostna degeneracija makule
US20120115925A1 (en) 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
WO2010085542A2 (en) 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP5651527B2 (ja) * 2011-05-02 2015-01-14 沖電気工業株式会社 無線端末装置、無線通信システム、プログラムおよび無線通信方法

Also Published As

Publication number Publication date
IL208555A (en) 2017-09-28
AU2009241348B2 (en) 2012-11-15
JP2011521623A (ja) 2011-07-28
CL2018000537A1 (es) 2018-07-20
US20090269338A1 (en) 2009-10-29
PH12014500519B1 (en) 2017-12-11
KR20130084330A (ko) 2013-07-24
CA2908470A1 (en) 2009-11-05
CN102066419A (zh) 2011-05-18
ZA201301709B (en) 2023-01-25
PL2283041T3 (pl) 2016-01-29
AU2009241348A1 (en) 2009-11-05
US9676868B2 (en) 2017-06-13
HK1193111A1 (zh) 2014-09-12
HK1245812A1 (zh) 2018-08-31
HK1147503A1 (en) 2011-08-12
IL208555A0 (en) 2010-12-30
US20160145349A1 (en) 2016-05-26
KR20110004451A (ko) 2011-01-13
EP2283041B1 (en) 2015-09-02
TW200944234A (en) 2009-11-01
PT2283041E (pt) 2015-11-24
EP2283041A1 (en) 2011-02-16
CL2009001001A1 (es) 2010-05-14
NZ621103A (en) 2015-10-30
US20140065137A1 (en) 2014-03-06
EP3002295A1 (en) 2016-04-06
EP3235829A1 (en) 2017-10-25
JP2013231045A (ja) 2013-11-14
MA32300B1 (fr) 2011-05-02
CA2720853C (en) 2015-12-29
CN103724433B (zh) 2015-11-18
CA2720853A1 (en) 2009-11-05
HUE026349T2 (en) 2016-06-28
JP5636359B2 (ja) 2014-12-03
SG189756A1 (en) 2013-05-31
RU2488594C2 (ru) 2013-07-27
AR071510A1 (es) 2010-06-23
US20140212433A1 (en) 2014-07-31
SI2283041T1 (sl) 2015-12-31
DK2283041T3 (da) 2015-12-07
ECSP10010637A (es) 2010-12-30
MX2010011342A (es) 2010-12-06
ES2552817T3 (es) 2015-12-02
CR11817A (es) 2011-01-13
KR101322027B1 (ko) 2013-10-30
JP5931008B2 (ja) 2016-06-08
AU2009241348C1 (en) 2013-03-28
US20120328613A1 (en) 2012-12-27
BRPI0907701A2 (pt) 2019-12-10
IL253014A0 (en) 2017-08-31
NZ588457A (en) 2012-12-21
EP3235829B1 (en) 2019-05-22
RS54405B1 (en) 2016-04-28
NZ603492A (en) 2014-05-30
PE20140806A1 (es) 2014-07-17
WO2009134711A8 (en) 2010-10-21
MY162350A (en) 2017-06-15
US20180100024A1 (en) 2018-04-12
PH12014500519A1 (en) 2017-12-11
TWI558413B (zh) 2016-11-21
TWI616456B (zh) 2018-03-01
US8273352B2 (en) 2012-09-25
US8614306B2 (en) 2013-12-24
WO2009134711A1 (en) 2009-11-05
MX2018013087A (es) 2020-09-02
CR20170001A (es) 2017-08-10
PE20091783A1 (es) 2009-12-04
IL266039A (en) 2019-06-30
US20190185579A1 (en) 2019-06-20
AR086272A2 (es) 2013-12-04
TW201437230A (zh) 2014-10-01
RU2010148423A (ru) 2012-06-10
SG10201608305SA (en) 2016-11-29
CY1116982T1 (el) 2017-04-05
HRP20151259T1 (hr) 2015-12-18
TW201819418A (zh) 2018-06-01
CN102066419B (zh) 2014-07-02
CN103724433A (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
CO6331346A2 (es) Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
CO6190543A2 (es) Anticuerpos anti-factor d humanizados
CO6700829A2 (es) Moduladores novedosos y métodos de uso
CO5720212A1 (es) Composicion de anticuerpo her2
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
RS54133B1 (en) ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES
RS54468B1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
CO6230999A2 (es) Anticuerpo anti-esclerostina
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
PE20120816A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
ES2721753T3 (es) Anticuerpos contra IL-6 y usos de los mismos
ES2585480T3 (es) Anticuerpo anti-NR10 y uso del mismo
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
CO6260094A2 (es) Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos
CR10563A (es) Anticuerpos monoclonales ant-il-6 y usos de los mismos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20120429A1 (es) Proteinas de enlace de miostatina
PE20080739A1 (es) Anticuerpos para il-17a

Legal Events

Date Code Title Description
FG Application granted